RxDoctor Payments Data

Coleman Ritchie, MD

Dermatology · Topeka, KSNPI 1497071716

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for dermatology clinicians in KS, where the typical reported total is $1,741.

$694in general payments, 2019–2025

Across 42 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$129
  • AbbVie$104
  • Lilly USA, LLC$93
  • LEO Pharma Inc.$68
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$56
  • Genentech USA, Inc.$38
  • plus $206 from 10 others

What the payments were for

  • Food & beverage$694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$694 in reported general payments places this provider in the 25th percentile of 82 dermatology providers in Kansas.

See all dermatology providers in Kansas

Medicare billing

Part B allowed, 2024
$929,971
Medicare patients
2,383
Services billed
10,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$102,348
Dupixent PenDupilumab13$48,646
Acitretin20$8,127
Tacrolimus37$5,770
Ketoconazole283$4,239
Clobetasol Propionate43$3,464
Doxycycline Hyclate108$1,580
Fluocinonide32$1,293
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc19$1,182
Triamcinolone Acetonide106$1,179
ValacyclovirValacyclovir Hcl22$1,041
Hydrocortisone79$678
Pentoxifylline20$482
Spironolactone42$462
Mupirocin60$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$16$102,34820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 82 dermatology providers in Kansas.

Other dermatology in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →